Literature DB >> 14666402

Improvement of the diagnostic procedure in proximal myotonic myopathy/myotonic dystrophy type 2.

Sibylle Jakubiczka1, Stefan Vielhaber, Wolfram Kress, Peter Küpferling, Ulrike Reuner, Bernhard Kunath, Peter Wieacker.   

Abstract

Proximal myotonic myopathy/myotonic dystrophy type 2 (PROMM/DM 2) is caused by an expansion of the (TG)n(TCTG)n(CCTG)n repeat tract in intron 1 of the ZNF9 gene located on chromosome 3q21. Because these expansions show a marked mitotic instability, expanded alleles are often difficult to detect. In order to improve the diagnostic procedure, we applied a combination of pulsed-field gel electrophoresis and semi-quantitative Southern blot analysis with a novel hybridization probe. The combination of these methods led to unequivocal results in about 98% of cases with a clinical diagnosis of PROMM/DM 2. Furthermore, we report the genotype/phenotype correlation in a patient lacking a normal ZNF9 allele and a further proband with a "grey zone" allele.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14666402     DOI: 10.1007/s10048-003-0168-6

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  8 in total

1.  Proof of genetic heterogeneity in the proximal myotonic myopathy syndrome (PROMM) and its relationship to myotonic dystrophy type 2 (DM2).

Authors:  W Kress; B Mueller-Myhsok; K Ricker; C Schneider; M C Koch; K V Toyka; C R Mueller; T Grimm
Journal:  Neuromuscul Disord       Date:  2000-10       Impact factor: 4.296

2.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

3.  Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9.

Authors:  C L Liquori; K Ricker; M L Moseley; J F Jacobsen; W Kress; S L Naylor; J W Day; L P Ranum
Journal:  Science       Date:  2001-08-03       Impact factor: 47.728

4.  Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum.

Authors:  J W Day; K Ricker; J F Jacobsen; L J Rasmussen; K A Dick; W Kress; C Schneider; M C Koch; G J Beilman; A R Harrison; J C Dalton; L P W Ranum
Journal:  Neurology       Date:  2003-02-25       Impact factor: 9.910

5.  Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene.

Authors:  M Mahadevan; C Tsilfidis; L Sabourin; G Shutler; C Amemiya; G Jansen; C Neville; M Narang; J Barceló; K O'Hoy
Journal:  Science       Date:  1992-03-06       Impact factor: 47.728

6.  An unstable triplet repeat in a gene related to myotonic muscular dystrophy.

Authors:  Y H Fu; A Pizzuti; R G Fenwick; J King; S Rajnarayan; P W Dunne; J Dubel; G A Nasser; T Ashizawa; P de Jong
Journal:  Science       Date:  1992-03-06       Impact factor: 47.728

7.  Genetic mapping of a second myotonic dystrophy locus.

Authors:  L P Ranum; P F Rasmussen; K A Benzow; M D Koob; J W Day
Journal:  Nat Genet       Date:  1998-06       Impact factor: 38.330

8.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

Authors:  J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

  8 in total
  4 in total

1.  Validation of sensitivity and specificity of tetraplet-primed PCR (TP-PCR) in the molecular diagnosis of myotonic dystrophy type 2 (DM2).

Authors:  Claudio Catalli; Alessandra Morgante; Raniero Iraci; Fabrizio Rinaldi; Annalisa Botta; Giuseppe Novelli
Journal:  J Mol Diagn       Date:  2010-07-08       Impact factor: 5.568

Review 2.  Myotonic dystrophy type 2 and related myotonic disorders.

Authors:  Giovanni Meola; Richard T Moxley
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

3.  Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2.

Authors:  Erik-Jan Kamsteeg; Wolfram Kress; Claudio Catalli; Jens M Hertz; Martina Witsch-Baumgartner; Michael F Buckley; Baziel G M van Engelen; Marianne Schwartz; Hans Scheffer
Journal:  Eur J Hum Genet       Date:  2012-05-30       Impact factor: 4.246

4.  Marathoning with myotonic dystrophy type 2 (proximal myotonic myopathy) and leukopenia.

Authors:  Josef Finsterer; Georg Safoschnik; Martina Witsch-Baumgartner
Journal:  SAGE Open Med Case Rep       Date:  2017-04-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.